| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
This linker does not have a biological target. Its functional groups target specific chemical moieties on other molecules. The primary amine (-NH2) can react with carboxylic acids or activated NHS esters to form amide bonds. The terminal carboxylic acid (-COOH) can be activated (e.g., with EDC/NHS) to react with amines. In the context of PROTACs, this linker connects the E3 ligase ligand to the target protein ligand. In ADCs, it serves as a non-cleavable spacer between the antibody and the cytotoxic payload.
|
|---|---|
| ln Vitro |
Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC targets and selectively degrades target proteins by means of the intracellular ubiquitin-proteasome system. An ADC cytotoxin is connected to an antibody by use of an ADC linker to form an ADC.
Amino-PEG5-acid itself does not possess intrinsic biological activity in cell-based assays. Its activity is defined by its use as a building block to create biologically active conjugates. For example, when used to synthesize a PROTAC, the resulting molecule can induce the degradation of a target protein in cells. The PEG5 spacer ensures that the conjugate remains soluble and flexible. In vitro, the conjugation efficiency of Amino-PEG5-acid to other molecules can be assessed by analytical techniques such as HPLC or mass spectrometry. |
| ln Vivo |
Amino-PEG5-acid is not intended for direct in vivo administration as a therapeutic agent. Its in vivo relevance is as a linker in the construction of ADCs, PROTACs, or other drug conjugates that are then administered in vivo. The PEG5 spacer in the final conjugate can influence its pharmacokinetics by increasing its hydrodynamic volume, reducing renal clearance, and extending its half-life in circulation. The non-cleavable nature of this linker ensures that the conjugate remains intact in the bloodstream.
|
| Enzyme Assay |
Non-cellular in vitro assays for Amino-PEG5-acid are chemical, not biological. They involve characterizing its purity and reactivity. For example, its purity can be determined by HPLC. Its reactivity can be assessed by activating the carboxylic acid with EDC/NHS and reacting it with a model amine-containing compound, such as a primary amine, and monitoring the formation of the amide bond by mass spectrometry or NMR. The reaction is typically carried out in an organic solvent such as DMSO or DMF.
|
| Cell Assay |
Cellular assays are not performed with Amino-PEG5-acid itself, but rather with the conjugates it helps create. For instance, a PROTAC synthesized using this linker can be tested in cell-based degradation assays. Cells expressing the target protein are treated with varying concentrations of the PROTAC for 6-24 hours. The levels of the target protein are then measured by Western blotting. The DC50 (concentration for 50% degradation) is determined from the concentration-response curve.
|
| Animal Protocol |
In vivo animal studies are performed with the final PROTAC or ADC synthesized using Amino-PEG5-acid, not with the linker itself. A typical protocol involves administering the conjugate intravenously to tumor-bearing mouse models. Mice are dosed with the conjugate at various concentrations on a schedule such as once weekly for 2-3 weeks. Tumor volume and body weight are measured regularly to assess efficacy and toxicity. Pharmacodynamic markers, such as target protein levels in tumor tissue, are also evaluated.
|
| ADME/Pharmacokinetics |
Amino-PEG5-acid is a chemical linker and does not have pharmacokinetic properties as an active drug. However, when used to create ADCs or PROTACs, the PEG5 linker influences the overall PK of the conjugate. The hydrophilic PEG spacer increases the hydrodynamic volume of the conjugate, reducing renal clearance and extending the half-life in circulation. The non-cleavable nature of the linker ensures that the conjugate remains intact in the bloodstream. For the linker itself, specific PK data are not available.
|
| Toxicity/Toxicokinetics |
Amino-PEG5-acid is a chemical reagent for research use only and is not intended for therapeutic or diagnostic use in humans. Toxicity data for the compound itself are limited, but standard laboratory safety precautions should be followed when handling it. As an amine- and acid-containing compound, it may cause irritation. In the context of ADC or PROTAC development, the toxicity is primarily attributed to the cytotoxic payload or the degradation of the target protein.
|
| References | |
| Additional Infomation |
Amino-PEG5-acid is a key building block in the field of bioconjugation and drug delivery. Its heterobifunctionality (amine and acid) allows for selective functionalization and conjugation. It is part of a broader family of PEG-based linkers used in the synthesis of ADCs and PROTACs. The compound is commercially available and is a standard reagent in many research laboratories. It is not a drug itself and has no clinical trial or regulatory approval status. Its value lies in its utility as a tool for creating more complex therapeutic molecules.
|
| Molecular Formula |
C13H27NO7
|
|---|---|
| Molecular Weight |
309.355984926224
|
| Exact Mass |
309.178
|
| CAS # |
1191078-74-6
|
| PubChem CID |
51035061
|
| Appearance |
Off-white to yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
446.0±45.0 °C at 760 mmHg
|
| Flash Point |
223.5±28.7 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.469
|
| LogP |
-2.28
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
21
|
| Complexity |
229
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(COCCOCCOCCOCCOCCN)C(=O)O
|
| InChi Key |
ZTYIBTVLGAIXDY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H27NO7/c14-2-4-18-6-8-20-10-12-21-11-9-19-7-5-17-3-1-13(15)16/h1-12,14H2,(H,15,16)
|
| Chemical Name |
3-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2325 mL | 16.1624 mL | 32.3248 mL | |
| 5 mM | 0.6465 mL | 3.2325 mL | 6.4650 mL | |
| 10 mM | 0.3232 mL | 1.6162 mL | 3.2325 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
